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Background: The optimal strategy for revascularization in infrainguinal chronic limb-threatening ischemia (CLTI) remains
debatable. Comparative trials are scarce, and daily decisions are often made using anecdotal or low-quality evidence.
Methods: We searched multiple databases through May 7, 2017, for prospective studies with at least 1-year follow-up that
evaluated patient-relevant outcomes of infrainguinal revascularization procedures in adults with CLTI. Independent pairs
of reviewers selected articles and extracted data. Random-effectsmeta-analysis was used to pool outcomes across studies.
Results: We included 44 studies that enrolled 8602 patients. Periprocedural outcomes (mortality, amputation, major
adverse cardiac events) were similar across treatment modalities. Overall, patients with infrapopliteal disease had higher
patency ratesof great saphenous veingraft at 1 and2 years (primary: 87%, 78%; secondary: 94%,87%, respectively) compared
with all other interventions. Prosthetic bypass outcomes were notably inferior to vein bypass in terms of amputation and
patency outcomes, especially for below knee targets at 2 years and beyond. Drug-eluting stents demonstrated improved
patencyoverbare-metal stents in infrapopliteal arteries (primarypatency: 73%vs50%at 1 year), andwasat least comparable
to balloon angioplasty (66% primary patency). Survival, major amputation, and amputation-free survival at 2 years were
broadly similarbetweenendovascular interventions and veinbypass,withprostheticbypasshavinghigher rates of limb loss.
Overall, the included studies were at moderate to high risk of bias and the quality of evidence was low.
Conclusions: There are major limitations in the current state of evidence guiding treatment decisions in CLTI, particularly
for severe anatomic patterns of disease treated via endovascular means. Periprocedural (30-day) mortality, amputation,
and major adverse cardiac events are broadly similar across modalities. Patency rates are highest for saphenous vein
bypass, whereas both patency and limb salvage are markedly inferior for prosthetic grafting to below the knee targets.
Among endovascular interventions, percutaneous transluminal angioplasty and drug-eluting stents appear comparable
for focal infrapopliteal disease, although no studies included long segment tibial lesions. Heterogeneity in patient risk,
severity of limb threat, and anatomy treated renders direct comparison of outcomes from the current literature chal-
lenging. Future studies should incorporate both limb severity and anatomic staging to best guide clinical decision
making in CLTI. (J Vasc Surg 2019;69:126S-36S.)
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morbidity, mortality, and public health implications.
There are various treatment options for CLTI, including
open and endovascular techniques of revascularization.
Comparing these different options is best done using
evidence from randomized controlled trials and
comparative studies. However, a recent systematic
review4 of comparative studies commissioned by the
Society for Vascular Surgery demonstrated a limited
evidence base and a small number of studies that
directly compared bypass surgery with endovascular
revascularization in patients with CLTI. Only nine studies
that enrolled 3071 subjects were included. There was no
signiﬁcant difference in mortality (odds ratio [OR], 0.72;
95% conﬁdence interval [CI], 0.44-1.16) or amputation
(OR, 1.2; 95% CI, 0.87-1.65). Bypass surgery was associated
with higher primary patency (OR, 2.50; 95% CI, 1.25-4.99)
and assisted primary patency (OR, 3.39; 95% CI, 1.53-7.51).
The quality of this evidence was deemed low for mortal-
ity and amputation outcomes and moderate for patency
outcomes.
Therefore, considering the lack of high-quality evidence
from comparative studies and to support the initiative of
a global vascular guideline on the management of these
patients, we sought to evaluate noncomparative evi-
dence derived from registries, trials, and prospective
cohort studies meeting speciﬁed reporting criteria. The
goal of this systematic review andmeta-analysis is to pro-
vide decision makers and guideline developers with
contemporary data on patient-important outcomes after
infrainguinal revascularization, to facilitate decision mak-
ing for patients with CLTI.
METHODS
The protocol was developed a priori by an expert panel
charged with developing a global guideline on the man-
agement of CLTI. This report follows recommendations
of the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses statements.5
Eligibility criteria. The search included comparative
and noncomparative prospective studies that enrolled
patients $18 years of age with critical or severe limb
ischemia (Rutherford 4-6, Fontaine 3-4) undergoing
infrainguinal (superﬁcial femoral artery [SFA], popliteal
artery, tibial artery, and pedal artery) revascularization
(endovascular or bypass surgery). Outcomes had to be
speciﬁcally reported based on the anatomic segment
treated and the intervention used. We included studies
that evaluated angioplasty/stent procedures (balloon
with and without drugs, and stent with and without
drugs), atherectomy, autogenous grafts, and nonautoge-
nous grafts. A minimum of 1-year follow-up was required
for inclusion. The outcomes of interest were mortality
and major amputation at 30 days, 1 year and yearly
thereafter up to 5 years; major adverse cardiovascularevents (MACE) and reintervention/readmission at
30 days; patency (primary, primary assisted, and sec-
ondary), amputation-free survival (AFS), reintervention
and amputation-free survival, quality of life, and wound
healing at 1 year and yearly thereafter up to 5 years as
available. All the outcomes were deﬁned according to
the study protocols. We extracted patency outcomes
only if the bypass graft or treated vessel was assessed
objectively using ultrasound or alternative imaging. We
restricted the inclusion criteria to prospective cohorts
with the sample size of at least 50 patients per endo-
vascular or bypass surgery approaches, and at least 20
patients per subtype of intervention reported.
Exclusion criteria.
1. Retrospective design or review article.
2. Common femoral artery, deep femoral artery, and
aortoiliac arteries.
3. Claudication (Rutherford 1-3, Fontaine 1-2).
4. Non-FDA-approved devices (balloon-expandable
absorbable metal stent).
5. Sample size <50 patients for either endovascular or
bypass surgery, or <20 patients in any subintervention
group.
6. The outcomes reported indistinctly in terms of the
location of lesions or of the subinterventions of our
interest.Data sources and search strategies. A comprehensive
search of several databases was conducted in any lan-
guage from 1990 for bypass surgery and 2000 for endo-
vascular procedures to May 7, 2017. The databases
included Ovid Medline In-Process & Other Non-Indexed
Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane
Central Register of Controlled Trials, Ovid Cochrane
Database of Systematic Reviews, and Scopus. The search
strategy was designed and conducted by an experi-
enced librarian with input from the study principal
investigator. Controlled vocabulary supplemented with
keywords was used to search for prospective cohort
studies and randomized controlled trials of critical limb
ischemia revascularization. The detailed search strategy
is available in the Appendix (online only).
Study selection and data extraction. After uploading
all the identiﬁed references to Web-based software
developed for systematic review data management
(DistillerSR, Evidence Partners, Ottawa, Ontario, Canada),
two reviewers screened all titles and abstracts indepen-
dently to assess the eligibility of each article. The relevant
references were retrieved in full text and screened
against eligibility criteria. We solved disagreements by
consensus. The ﬁnal included studies were extracted
using standardized forms created in DistillerSR. We
extracted data from text and tables, and we used Web
Plot Digitizer6 as a measurement tool to extract data
from graphs (Kaplan-Meier curves).
Fig 1. Process of studies selection.
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analysis was to establish the best estimates for incidence
rates of clinically important outcomes stratiﬁed by the
anatomic level of disease treated. Therefore, outcome
measures were derived from noncomparative data.
Consequently, we derived risk of bias indicators (meth-
odologic quality) from the Newcastle-Ottawa7 instru-
ment removing comparability items. We focused on
outcome ascertainment (hemodynamic assessment at
baseline and follow-up, independent event adjudication,
core lab imaging assessment) and adequacy of follow-up.
Analysis. We reported the outcomes from noncompar-
ative studies as cumulative incidence rates with 95% CI
estimated using the binominal distribution. Then, we
pooled the log transformed rates using the DerSimonian
and Laird random-effects model8 and estimated het-
erogeneity using the Mantel-Haenszel model if possible.
To evaluate heterogeneity, we calculated I2 statistic,9
where I2 > 50% suggests high heterogeneity and not
applicable (NA) suggests only one study available for
analysis. We used STATA, version 14 (StataCorp LP, Col-
lege Station, Tex) for conducting statistical analyses.
Whenever possible, we planned to stratify analysis by:
1. Location of disease (endovascular: SFA, popliteal, and
infrapopliteal; bypass surgery: Fem-pop above the
knee, fem-pop below the knee, infrapopliteal, and
any infrainguinal location)
2. Direct vs indirect revascularization3. Stent type-bare metal; balloon-expandable vs self-
expandable
4. Endovascular techniques vs each other by location
5. Rest pain vs tissue loss
6. Diabetes status vs not
7. End-stage renal disease vs not
8. Multicenter vs single-center study.
We used the Global Limb-based Anatomic Staging
System (GLASS; Table 1 in the Appendix, online only) to
summarize the treated lesion distribution for the endo-
vascular studies included in the review. We reported
GLASS grades for femoropopliteal (FP) and tibioperoneal
lesions separately using the location of the injured vessel,
degree of stenosis, and the length of lesions as criteria for
grading, based on data available from the published
report of each study. Higher grade number (0-4) in
GLASS represents a more severe lesion at each anatomic
level.RESULTS
Study identiﬁcation
The search strategy yielded 3165 citations, and manual
search of previous systematic reviews added an addi-
tional 406 citations. We explained the study selection
process in Fig 1. After excluding all irrelevant studies, we
included 44 studies in the meta-analysis enrolling 8602
patients. Fig 2 depicts the subcategories of data sources
Fig 2. Subcategories of data sources used by the revascularization technique, anatomical location, and conduits
types. Some studies contained data in more than 1 category. BMS, Bare-metal stent; DEB, drug-eluting balloon;
DES, drug-eluting stent; Fem-pop ATK, femoropopliteal above the knee; Fem-pop BTK, femoropopliteal below the
knee; POBA, plain old balloon angioplasty; SFA, superﬁcial femoral artery.
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location, and conduits types. The characteristics of the
included studies are summarized in the Supplementary
Tables in the Appendix (Table 2.1 for endovascular studies
and Table 2.2 for bypass surgery studies, online only). The
criteria used to assess the risk of bias showed that most
of the studies appeared to have moderate to high risk
of bias (Table 4 in the Appendix, online only).
Several key limitations of the available data are readily
apparent from the summary tables, deﬁning major gaps
in quality evidence for the ﬁeld. For FP disease, there
were no studies that could be included on stenting
despite the highly prevalent use of stents for this level of
disease. This reﬂects the fact that regulatory trials andpro-
spective studies of stenting for FP disease have focused
primarily on subjects with moderate lesion severity, pre-
dominantly thosewith claudication, oftenmixing in small
percentages of patients with CLTI (rest pain) without
clearly separating the outcomes by indication. Overall,
the endovascular data are also quite limited in terms of
the spectrum of anatomic severity treated, both above
and below the knee (eg, no studies included GLASS grade
4 IP disease). For open FP bypass surgery, thereweremore
studies included of prosthetic conduits than of autoge-
nous vein, likely because the superiority of autogenous
vein bypass has long been considered as established.
Finally, the number of patients included with data avail-
able beyond 2 years was also a notable limitation.Outcomes
In the Appendix (Tables 3.1-3.6, online only), we summa-
rize the results of meta-analyses of the included 44
studies for all available procedure types per time point
of interest. Figs 3-7 depict overall outcomes as propor-
tions and associated 95% CI for endovascular and open
bypass surgery in the ﬁrst year and the third year of
follow-up according to the location of lesions. An over-
view summary is provided in the following text. Data
were insufﬁcient to conduct several a priori planned
subgroup analyses such as diabetes status, a diagnosis
of ESRD, certain technical aspects, lesion severity, and
number of study centers.
Periprocedural events
Perioperative mortality (1%-7%) rates were similar across
treatment types and lesion locations. MACE (1%-7%)
andmajor amputation (0%-7%) rates were likewise similar
between endovascular interventions and vein bypass
surgery. Early amputation rates after nonautogenous
bypass graftingwere notably higher than great saphenous
vein bypass and ectopic/spliced vein bypass (up to 14%).
Mid- to long-term outcomes
Endovascular. At 1 year, primary patency of percuta-
neous transluminal angioplasty (PTA) and atherectomy
in patients with SFA lesions were 0.86 (95% CI, 0.70-1.00;
I2 ¼ 84.1%) and 0.73 (95% CI, 0.58-0.85; I2 ¼ NA), respec-
tively. As noted above, there were no data available for
Fig 3. Forest plot represents the overall outcomes’ proportions and associated 95% conﬁdence intervals
(CIs; horizontal lines) for each endovascular technique at 1 year and 3 years of follow-up in patients with infra-
popliteal arteries lesions.
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pliteal artery lesions, primary patency at 1 year was as
follows: bare-metal stent (BMS): 0.50 (95% CI, 0.42-0.60;
I2¼ 41.4%); drug-eluting stent (DES): 0.73 (95%CI, 0.65-0.81;
I2 ¼ 68.1%); atherectomy: 0.78 (95% CI, 0.72-0.85; I2 ¼ 0%);
and PTA: 0.66 (95% CI, 0.51-0.85; I2 ¼ 84.1%).
At 3 years, in patients with infrapopliteal artery lesions,
primary patency of DES was 0.49 (95% CI, 0.31-0.79;
I2 ¼ 79.8%), and that of BMS was 0.10 (95% CI, 0.03-
0.23; I2 ¼ NA). No data were available for PTA alone at
this time point. Data on major amputation and mortality
in patients with infrapopliteal disease were not signiﬁ-
cantly different for various endovascular techniques at 1
and 3 years of follow-up.Bypass surgery. For bypass surgery to any infrainguinal
target, the incidence rate of major amputation within
1 year was 0.11 (95% CI, 0.09-0.13; I2 ¼ NA) in great saphe-
nous vein graft, 0.24 (95% CI, 0.14-0.42; I2 ¼ 76.8%) in non-
autogenous graft, and 0.16 (95% CI, 0.12-0.21; I2 ¼ NA) in
ectopic vein or spliced arm vein graft. On the other
hand, primary patency at 1 year was 0.77 (95% CI, 0.71-
0.82; I2 ¼ 0%) in nonautogenous grafts, 0.64 (95% CI,
0.61-0.67; I2 ¼ NA) in great saphenous vein grafts, and
0.45 (95% CI, 0.39-0.51; I2 ¼ NA) in ectopic vein or spliced
arm vein graft. At 2 years and beyond, superior patency
(primary and secondary) and limb salvage rates for great
saphenous vein over nonautogenous and ectopic vein
conduits were evident and increasingly ampliﬁed.
Fig 4. Forest plot represents the overall outcomes’ proportions and associated 95% conﬁdence intervals
(CIs; horizontal lines) for nonautogenous graft at 1 year and the third year of follow-up in patients with femo-
ropopliteal (FP) above-the-knee lesions.
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Data on MACE, reintervention/readmission, AFS, reinter-
vention and amputation-free survival, quality of life, and
wound healing were limited.
Quality of the evidence
Using the GRADE approach (Grading of Recommenda-
tions, Assessment, Development and Evaluation),10 the
current evidence warrants low conﬁdence as it was
derived from noncomparative studies at moderate to
high risk of bias. This applies to all outcomes of interest
addressed in this review.DISCUSSION
This systematic review and meta-analysis provides inci-
dence rates of several patient important outcomes for
patients with infrainguinal CLTI requiring either opensurgical or endovascular intervention. This information,
along with surgical expertise, can support shared deci-
sion making and possibly populate decision aids that
facilitate conversations taking place during the clinical
encounter. However, there are notable limitations to
the current state of evidence in CLTI that are
re-emphasized by this review. Commonly employed pro-
cedures such as stent placement for FP lesions have not
been adequately studied in a prospective manner in the
CLTI population. Lesion severity in the endovascular
cohorts is greatly limited by the regulatory nature of
many of the reported studies, focused on subjects with
more favorable lesions, and thus lacking generalizability
to a large segment of the real-world population with
CLTI. Moreover, these studies universally lack information
on both patient risk and the severity of limb threat (eg,
SVS threatened limb classiﬁcation system) that is likely
Fig 5. Forest plot represents the overall outcomes’ proportions and associated 95% conﬁdence intervals
(CIs; horizontal lines) for each bypass surgery graft at 1 year and 3 years of follow-up in patients with femo-
ropopliteal (FP) below-the-knee lesions.
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and major amputation. With these numerous important
confounders, any direct comparisons of outcomes must
be considered highly speculative and the importance
of high-quality, appropriately stratiﬁed randomized
controlled trials is stressed.
The assessment of patency of revascularization and the
relationship between patency and important clinical end
points in CLTI such as reintervention, major adverse limb
events, and amputation represent areas of inconsistent
reporting and controversy in the literature, and among
vascular specialists. Maintained patency of the bypass
graft or endovascular intervention is unarguably a
desired outcome for any revascularization, reducing the
likelihood of recurrent symptoms, repeated procedures
and hospitalizations, and downstream major adverselimb events. Surveillance protocols, assessment of vessel
patency, and approach to reinterventions for endovascu-
lar procedures and bypass grafts vary across studies and
greatly inﬂuence the reported outcomes. For example,
prophylactic reinterventions for vein bypass graft lesions
identiﬁed on ultrasound surveillance are commonly per-
formed with the goal of maintaining long-term primary
assisted patency, resulting in reduced midterm primary
patency rates in comparison to prosthetic grafts. Despite
these caveats, a global assessment of primary, primary
assisted, and secondary patency provides an important
lens into the expected anatomic durability of the given
reconstruction.
This contemporary evidence review was designed to
inform a comprehensive practice guideline on the man-
agement of CLTI, and thus the criteria we employed for
Fig 6. Forest plot represents the overall outcomes’ proportions and associated 95% conﬁdence intervals
(CIs; horizontal lines) for each bypass surgery graft at 1 year and 3 years of follow-up in patients with infrapopliteal
arteries lesions.
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ingly, studieswith inadequate numbers of patients or pro-
cedures, limited follow-up, or where the outcomes
reported were indistinct in relation to the anatomic level
of disease and the speciﬁc procedure performed were
excluded. These strict inclusion criteria may have led to a
smaller body of evidence on stenting. In clinical practice,
specialists are faced with an array of choices and an esti-
mate of risk/beneﬁt for each is based on speciﬁc patient
factors such as general health, anatomic pattern of dis-
ease, and conduit availability. Other recent registry studies
and reviews examining outcomes of endovascular inter-
vention or surgery have employed different study designs
for alternative purposes.11-13 Of note, although employing
different and less restrictive inclusion criteria, a recentmeta-analysis of infrapopliteal PTA reported very similar
1-year point estimates of primary patency (0.63 vs 0.66
[95% CI, 0.51-0.85] this study), major amputation (0.15 vs
0.08 [95% CI, 0.03-0.25] this study), and mortality (0.15 vs
0.15 [95%CI, 0.11-0.22] this study).14Only 2 studies included
in that report involved tibial lesion lengths >88 mm,
although multiple studies included patients with tibial
occlusions. The referable GLASS IP grades encompassed
in that meta-analysis are predominantly 1 and 2, with
few if any IP grade 3 or 4 lesion patterns represented.
Despite these key limitations, the available data sug-
gest that periprocedural risks are broadly similar across
both open and endovascular interventions for CLTI in
current practice. For endovascular interventions, there is
little evidence to support favoring any one technique in
Fig 7. Forest plot represents the overall outcomes’ proportions and associated 95% conﬁdence intervals
(CIs; horizontal lines) for each bypass surgery graft at 1 year and 3 years of follow-up in patients with any
infrainguinal artery lesions.
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commonly encountered. DES appears to offer improved
outcomes over BMS for short infrapopliteal lesions, and
may thus be a preferred bailout option for ﬂow-limiting
dissection or PTA failures in this group. Bypass surgery
with autogenous vein offers the best mid- and long-
term patency and limb salvage outcomes, particularly
for below-knee targets. Open bypass with nonautoge-
nous conduits has inferior patency and limb salvage out-
comes at all time points.
Clinical implications. CLTI is a highly morbid condi-
tion and successful treatment requires safe and effec-
tive limb revascularization. There is a broad range ofpatient risk, limb threat and anatomic severity in this
population, and a lack of high-quality comparative
trials. In current practice, specialists should be familiar
with the full range of endovascular and open surgical
techniques for revascularization. Although overall sur-
vival and AFS are largely similar across studies applying
various modalities in selected patients, signiﬁcant dif-
ferences in anatomic durability of interventions are
apparent beyond 1 to 2 years. These factors should be
taken into account when undertaking clinical decision
making in this population. Overall, it seems that major
adverse events seen in patients with CTLI did not
importantly differ between endovascular and open
bypass. Increased patency did not always correlate
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tation, which may be a limitation of the available
evidence.
Strengths and limitations. This systematic review is the
most comprehensive and up to date addressing this topic.
The strengths of this review relate to a priori design that
restricted inclusion to studies that were prospective with
adequate follow-up and procedures, the comprehensive
search that included multiple databases, the rigorous
approach of study selection and appraisal by pairs of
independent reviewers, and collaboration with clinical
experts tasked with developing a global guideline on CLTI.
The limitations of this review relate to the nature of data
available and our inability to stratify results by several
clinically important characteristics that restricts the ability
of providing patients with individualized risk assessment
speciﬁc to their lesion and clinical context. Other sources
of data such as institutional and multi-institutional regis-
tries may be of value, particularly for hard objective end
points such as mortality and amputation, but are fraught
with less rigorous inclusion criteria, inconsistent follow-
up assessments and reporting of outcomes speciﬁc to
the anatomy treated or procedure employed, and signiﬁ-
cant proportions of subjects with missing data. Further
efforts should focus on improving data quality in prospec-
tive registries andcomparative effectiveness studies in this
growingpopulationwith advancedPAD. Thequality of ev-
idence supporting the care of patients with CLTI remains
low, and the choice of approach remains heavily depen-
dent on patients’ values, morbidities, provider bias, and
the availability of endovascular and surgical expertise
wherever they are treated.
CONCLUSIONS
Multiple revascularization techniques are currently
available for the treatment of CLTI. Optimal selection of
interventions requires the understanding of the current
evidence within the context of the individual patient’s
clinical status, disease severity, and anatomic pattern.
Results from current large-scale randomized trials15,16
will be of great value in moving toward true evidence-
based revascularization for CLTI.
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